Collate

Collate

About Collate

Simplify's Rating
Why Collate is rated
B-
Rated D+ on Competitive Edge
Rated A on Growth Potential
Rated B on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

N/A

Company Stage

Seed

Total Funding

$29.2M

Headquarters

San Francisco, California

Founded

2025

Overview

YC Company
πŸš€
Launched Recently
Simplify Jobs

Simplify's Take

What believers are saying

  • Collate secured $30M in funding, indicating strong investor confidence and market potential.
  • There's a growing demand for AI-driven automation in life sciences to enhance R&D efficiency.
  • Potential partnerships with biotech firms could expand Collate's market reach and integration.

What critics are saying

  • Competition from established AI automation companies like UiPath and Automation Anywhere is increasing.
  • Ethical and regulatory challenges in automating sensitive medical documentation could arise.
  • Rapid AI advancements may render Collate's solutions obsolete without continuous innovation.

What makes Collate unique

  • Collate focuses on automating paperwork in the life sciences industry using AI.
  • The company is led by experienced founders Surbhi Sarna, Nate Smith, and Jigish Patel.
  • Collate targets diagnostic, medical device, and drug development companies for streamlined documentation.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$29.2M

Above

Industry Average

Funded Over

1 Rounds

Notable Investors:
Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Above Average

Industry standards

$3.3M
$2M
Netflix
$2.3M
Instacart
$3M
Robinhood
$30M
Collate

Company News

American Bazaar
Jan 21st, 2025
Collate secures $30M to automate paperwork

Biotech startup Collate, founded by Surbhi Sarna, has secured a $30 million seed fund to automate paperwork in the life sciences industry using AI. The funding round was led by Redpoint, with participation from First Round, Conviction Partners, and YC, valuing Collate at over $100 million. Collate aims to streamline documentation for diagnostic, medical device, and drug development companies, enhancing R&D and reducing time to market. Co-founders Nate Smith and Jigish Patel bring additional expertise.

Forbes
Jan 13th, 2025
This YC Partner Just Raised $30 Million For An AI Startup Automating Paperwork For Biotech

Y Combinator's Surbhi Sarna has raised $30 million for Collate, a startup aiming to automate the tedious parts of running a life sciences business using AI.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Collate right now.

Find jobs on Simplify and start your career today

πŸ’‘
We update Collate's jobs every 8 hours, so check again soon! Browse all jobs β†’